ALX Oncology Q2 net loss $32.9M ($0.81 EPS); FDA fast track and ODD for evorpacept

ALX ONCOLOGY HOLDINGS INC

2022-Q2 EPS reported -$1.41

Net loss GAAP $32.9M ($0.81/share) vs $16.3M ($0.40) in Q2 2021; R&D spend $26.7M vs $11.2M.
Cash/investments $324.2M sufficient to fund operations through Q4 2024.
FDA granted Fast Track designation for evorpacept in 1st-line PD-L1+ HNSCC; ODD for AML.
ASPEN-05 (AML) Phase 1 dose escalation completed; enrollment paused for dose optimization pending ASPEN-02 data.
ASPEN-06 gastric/GEJ Phase 2 results expected 2023; ASPEN-07 (UC) initiation planned Q4 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.